In accordance with the proposed mechanism for how MDM2 can induce breast cancer resistance to CDK4/6 inhibitors, preclinical studies have evaluated the effects of MDM2 inhibitors on the growth of CDK4/6-resistant tumors. This evidence concerns the gene MDM2 and breast carcinoma.